Trastuzumab is a humanized anti-HER2 monoclonal antibody used for the treatment of HER2-positive breast cancer, however, most patients eventually develop resistance to the drug within 1–2 years [8–10]. The gene discussed is ERBB2; the disease is breast cancer.